“The main diagnostic challenge with prostate cancer lies in identifying cancers requiring rapid treatment and those requiring only active surveillance, while avoiding unnecessary biopsies,”, “For this reason, optimal patient outcomes depend on the rapid and accurate diagnosis and treatments that AI technologies can potentially help provide.” stated said David Gruen, M.D., Chief Medical Officer, Imaging, IBM Watson Health. “With IBM Watson Health, we will be leveraging progress made under the initial liver collaboration for the purposes of this second project dedicated to prostate cancer, with the same aim of delivering augmented intelligence to help radiologists and oncologists. This partnership is in line with Guerbet’s commitment to developing ambitious medical solutions to speed up diagnosis, improve the patient experience, and reduce clinical risks and costs,” stated François Nicolas, Chief Digital Officer for Guerbet.To learn more about International Business Machines Corp (IBM) and to track its ongoing progress please visit the Vista Partners IBM Coverage Page. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Oct1(2)
IBM Watson Announces Agreement With A Leading Diagnostic & Imaging Specialist To Upgrade Prostate Cancer Treatment
Dow 30 component International Business Machines Corporation (IBM) provides information technology (IT) products and services worldwide. IBM announced recently two significant quantum processor upgrades for its IBM Q early-access commercial systems. These upgrades represent rapid advances in quantum hardware as IBM continues to drive progress across the entire quantum computing technology stack, with a focus on systems, software, applications, and enablement. As per reports, IBM Watson Health has entered into an agreement with Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging. The partnership, which follows the first agreement between both the companies to help monitor patients with lung cancer will now allow artificial intelligence (AI) to help diagnose and monitor patients with prostate cancer and help detect, segment, characterize and monitor patients over time allowing a faster and informed diagnosis. The AI inclusion is compatible with the majority of PACS visualization systems assisting radiologists and oncologists with direct integration.
Post View Count : 861